AI주식인사이트AI Stock Insight
C

셀루메드

049180KOSDAQ

50.5 / 100

Reference Date: 2026-10-23

Financial Score18.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Cellumed operates in various sectors including medical devices, biologics, and cosmeceuticals, focusing on tissue engineering-based medical devices and growth factor manufacturing. The company is expanding into mRNA vaccine production enzyme development, secondary battery, and electric bicycle businesses, aiming for overseas market entry. It also diversifies through subsidiaries engaged in environmental engineering and real estate development.

Number of Employees

83people

Average Salary

48.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
10.01Industry Average 1.200.0Point

8.3x industry avg (risky)

ROE
-25.02Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
23.59Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲21.9% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲29.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -106.8% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (18%, downtrend)

Current 1,009Won52-week high 2,57052-week low 660
1-month return3.0Point

1m 0% (flat)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-10-13
  • Neutral[기재정정]반기보고서 (2026.06)2026-10-13
  • Neutral[기재정정]주주명부폐쇄기간또는기준일설정2026-10-13